Warfarin monitoring and reversal

01Purpose and principlesWhat the treatment does and how it fits into care.

Warfarin has a narrow therapeutic index, multiple interactions and a delayed pharmacodynamic response, but remains essential for mechanical valves and useful when DOACs are unsuitable. Its effect reflects turnover of vitamin-K-dependent factors rather than the plasma drug concentration. Factor VII falls early, so an initial INR rise does not mean full antithrombotic effect; factor II takes longer. In acute VTE, overlap a therapeutic parenteral anticoagulant for at least 5 days and until the INR is adequately therapeutic. Initiation schedules should be locally validated and reduced or supervised closely in older, frail, malnourished, liver-impaired or heart-failure patients.

The target must be stated, not assumed. Many AF and VTE indications use target 2.5, range 2.0–3.0. Mechanical valves use valve-specific targets based on thrombogenicity, mitral versus aortic position and embolic risk; obtain the operation card or cardiology plan. Time in therapeutic range measures control over time, but any acute high INR must be acted on now. Investigate a change before repeatedly altering dose: adherence, duplicate tablets, antibiotics, amiodarone, antifungals, anticonvulsants, alcohol, reduced intake, diarrhoea, fever, liver dysfunction and heart failure are common causes.

Reversal is determined by bleeding, site and urgency, not INR alone. Major or life-threatening bleeding needs immediate four-factor PCC for rapid factor replacement and IV phytomenadione for sustained correction. A product such as Beriplex is dosed by pretreatment INR and body weight up to 100 kg: 25 IU/kg for INR 2.0–3.9, 35 IU/kg for 4.0–6.0 and 50 IU/kg above 6.0, with maxima 2500, 3500 and 5000 IU. Follow the stocked product's protocol. Recheck INR and haemostasis; repeated PCC is not routine because it increases thrombotic exposure and may not correct an uncontrolled source.

For excessive INR without bleeding, avoid the harm of over-reversal. At INR 5–8, omit warfarin, identify the cause and restart at a lower dose when in range; give low-dose vitamin K only when bleeding risk warrants. Above INR 8, omit warfarin and give oral phytomenadione, commonly 1–5 mg, then repeat INR within the local timeframe. Minor bleeding needs local haemostasis plus an INR-led pathway; clinically important bleeding may justify vitamin K even below the major threshold. Vitamin K route and dose matter: IV acts faster but must be infused slowly because severe reactions can occur, while large doses can cause prolonged warfarin resistance.

Interruption requires thrombotic as well as procedural assessment. Many low-bleeding-risk procedures can continue warfarin within a defined INR; others require timed cessation, commonly 5 days, and pre-procedure INR confirmation. Bridging is not routine for AF because it increases bleeding. It is reserved for selected high-risk mechanical valves or very recent or severe thrombosis under a written plan. Restart after procedural haemostasis, considering whether post-operative therapeutic dosing is immediately safe. Never improvise bridging solely because an INR has become subtherapeutic.

Key points

Warfarin inhibits vitamin-K recycling and lowers functional factors II, VII, IX and X; the delayed fall and recovery mean INR changes lag behind dose changes.
Use an indication-specific target, commonly target INR 2.5 with range 2.0–3.0 for VTE and AF; mechanical valve targets depend on valve type, position and additional embolic risks.
Monitor INR more frequently during initiation and after illness, interacting medicine, diet or alcohol change, missed doses or unstable control; stable patients can move to longer locally defined intervals.
Major bleeding: stop warfarin and give four-factor PCC plus 5–10 mg slow IV phytomenadione; vitamin K alone is too slow and plasma is not routine first-line replacement when PCC is available.
No bleeding with INR above 8: omit warfarin and give 1–5 mg oral phytomenadione, then recheck promptly and repeat if necessary according to the UK protocol and patient risk.
No bleeding with INR 5–8: omit one or two doses and investigate the cause; vitamin K is not routinely required unless individual bleeding risk is high.
PCC dosing is product and INR based: for Beriplex, 25, 35 or 50 IU factor IX/kg for INR 2–3.9, 4–6 or above 6 respectively, with stated maximum doses.
Bridge acute VTE with therapeutic heparin for at least 5 days and until the INR has been therapeutic for the protocol-defined period because early protein C depletion is not immediate protection.
Provide an anticoagulant record and consistent advice on missed doses, vitamin-K-containing food, alcohol, interacting medicines, pregnancy and when to seek urgent help.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Bleeding severity

Classify critical-site, haemodynamic or ongoing major bleeding separately from minor bleeding and an isolated high INR because reversal intensity differs.

INR trajectory

Review current and prior results, tablet strengths and recent dose changes; a rising INR after a held dose may reflect delayed interaction or illness.

Interaction pattern

Antibiotics, azole antifungals, amiodarone, anticonvulsants, NSAIDs, antiplatelets, alcohol and reduced nutrition change anticoagulant effect or bleeding independent of INR.

Thrombotic indication

Mechanical mitral valves, recent VTE and selected severe thrombophilia carry different interruption risk from stable AF without recent embolism.

Occult toxicity

Fatigue, dyspnoea, melaena, haematuria, headache, abdominal or back pain may reveal significant bleeding before hypotension develops.

Red flags requiring action

New neurological deficit, severe headache, collapse or head injury while taking warfarin requires emergency intracranial imaging and reversal assessment irrespective of an apparently modest INR.
Haemodynamic instability, ongoing gastrointestinal bleeding, haemoptysis, haematuria with obstruction or a rapid haemoglobin fall requires major-haemorrhage escalation and source control.
An INR above 8, interacting antibiotic, acute liver or renal failure, inability to take nutrition or repeated dosing error predicts further INR rise even when bleeding is not yet visible.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line: urgent INR and FBCFirst stepFirst line
Why
Quantify anticoagulant intensity and detect haemoglobin or platelet consequences.
Interpretation and limitations
Treat life-threatening bleeding immediately rather than waiting for INR. A normal platelet count does not exclude major haemorrhage, and haemoglobin may initially remain normal after acute loss.
02
Renal, liver and coagulation profile
Why
Find organ dysfunction or another coagulopathy contributing to bleeding or INR instability.
Interpretation and limitations
Acute liver failure, malnutrition, sepsis and DIC can prolong INR independently; fibrinogen and APTT help define a broader haemostatic defect but do not measure warfarin alone.
03
Medication and dose reconciliation
Why
Identify dosing error, duplication or a pharmacokinetic interaction that will persist after initial correction.
Interpretation and limitations
Check actual tablets, anticoagulant record, prescriptions, over-the-counter analgesia, antimicrobials, supplements, alcohol and recent missed or extra doses.
04
Site-directed imaging or endoscopy
Why
Find a critical or treatable source while reversal and resuscitation proceed.
Interpretation and limitations
Use immediate CT head for neurological symptoms or significant head injury and activate gastrointestinal, trauma, obstetric or surgical haemorrhage pathways according to presentation.
05
Post-reversal INR
Why
Confirm factor replacement and sustained vitamin-K response.
Interpretation and limitations
Recheck after PCC according to the major-haemorrhage protocol and again for rebound; persistent bleeding despite corrected INR points to source, thrombocytopenia, fibrinogen deficiency or another mechanism.

04Treatment approachPreparation, options, escalation and aftercare.

01Major bleedingReverse immediately and control sourceFirst stepBleeding is life-threatening, at a critical site, haemodynamically significant or uncontrolled.

1Stop warfarin, use ABCDE resuscitation, activate major-haemorrhage and obtain urgent INR, FBC, fibrinogen, renal, liver and group samples.
2Give four-factor PCC using the stocked product's INR and weight schedule plus 5–10 mg slow IV phytomenadione.
3Control the anatomical source, repeat INR and clinical assessment, then create a multidisciplinary anticoagulation restart plan.

02High INR without bleedingHold and correct proportionatelyA surveillance INR is supratherapeutic but there is no clinically evident bleeding.

1Confirm the result, examine for occult bleeding and identify dose, illness, intake and interaction causes.
2For INR 5–8 omit warfarin and consider low-dose vitamin K only for high bleeding risk; above 8 give 1–5 mg oral phytomenadione.
3Repeat INR promptly, restart at an adjusted dose when safe and shorten monitoring until the cause and control are stable.

03Planned procedureMatch interruption to both risksAn invasive procedure is planned in a patient taking stable warfarin.

1Obtain procedure bleeding risk, indication, target INR, recent thrombosis and exact mechanical-valve details.
2Continue for supported low-risk procedures or stop at the locally specified interval and confirm pre-procedure INR; use bridging only when thrombotic risk justifies it.
3Restart when haemostasis permits, with a written timing and any bridging plan communicated across teams.

04Unstable INRCorrect the cause before chasing dosesRepeated results are outside range or time in therapeutic range is poor.

1Reconcile tablets, adherence, diet, alcohol, illness and all prescribed, non-prescribed and herbal medicines.
2Make a proportionate weekly-dose adjustment using the anticoagulation service protocol and schedule an earlier INR.
3AlternativeIf instability persists, reassess suitability for the indication, adherence support and whether an alternative anticoagulant is permitted.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Long-term vitamin K antagonist for mechanical valves, thrombotic APS and other indications where DOACs are unsuitable or not supported.

Warfarin

Use a locally validated oral loading protocol and adjust the total weekly dose to the stated target INR; acute VTE additionally requires therapeutic heparin for at least 5 days and until INR is therapeutic for the locally defined interval.

Check interacting medicines, liver function, nutrition, alcohol and adherence. Provide an anticoagulant record and close INR monitoring after change. It crosses the placenta and can cause embryopathy and fetal bleeding; pregnancy and conception require specialist planning.

Restores hepatic production of functional vitamin-K-dependent factors and sustains correction after short-lived infused factor replacement.

Phytomenadione

For major warfarin bleeding give 5–10 mg by slow intravenous injection with four-factor PCC; for INR above 8 without bleeding give 1–5 mg orally, then recheck and repeat only according to response and protocol.

IV administration must be slow because severe anaphylactoid reactions have occurred. Oral treatment is slower and unsuitable as sole emergency therapy. Avoid unnecessarily large doses because prolonged warfarin resistance can complicate re-anticoagulation.

Rapidly replaces factors II, VII, IX and X for life-threatening or major vitamin-K-antagonist bleeding or urgent reversal when immediate haemostasis is required.

Four-factor prothrombin complex concentrate

For Beriplex major warfarin bleeding give 25 IU factor IX/kg when INR 2.0–3.9, 35 IU/kg when INR 4.0–6.0 or 50 IU/kg when INR exceeds 6.0; maxima are 2500, 3500 and 5000 IU and weight is capped at 100 kg.

Give with vitamin K and follow the exact stocked product protocol. PCC can cause arterial or venous thrombosis and DIC; balance this against haemorrhage, monitor response and avoid routine repeat dosing without senior haematology input.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

During initiation, measure INR at the frequency specified by the loading protocol and do not infer stable maintenance need from the first response.
Once stable, extend testing through the anticoagulation service schedule, but shorten immediately after interacting drugs, acute illness, intake change, missed doses, bleeding or a dose adjustment.
Track time in therapeutic range and investigate persistent values below 65% rather than accepting oscillation as inevitable; assess cognition, access, adherence and suitability of the indication.
After PCC and vitamin K, repeat INR and clinical haemostasis at protocol-defined times, monitor for rebleeding and thrombosis and ensure the underlying source is controlled.
At each review verify the current target, valve or thrombotic indication, duration, concurrent antiplatelet need, pregnancy plans and peri-procedural instructions.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

INR is not severity

A patient can have fatal intracranial bleeding at a modest INR or remain asymptomatic at a very high INR; anatomy and physiology determine emergency action.

Vitamin K sustains PCC

PCC supplies functioning factors immediately but they decay. Intravenous phytomenadione enables endogenous replacement and reduces rebound anticoagulation.

Interaction effects lag

Because factor half-lives differ, an INR may continue rising after warfarin is withheld; the interacting medicine and reduced intake can outlast the dose change.

Bridge selectively

Peri-procedural LMWH increases bleeding and is not a badge of adequate care. Reserve it for clearly high thrombotic risk under a timed written plan.

Tablets create traps

Multiple strengths and alternating doses cause error. Confirm colour, strength and schedule directly and simplify the weekly regimen whenever control permits.

08Common pitfallsFrequent interpretation and management errors.

01
Do not wait for an INR before reversing known warfarin exposure with life-threatening bleeding; draw blood, then treat while source control proceeds.
02
Do not give fresh frozen plasma routinely when four-factor PCC is available; plasma is slower, larger volume and less reliable for rapid vitamin-K-factor replacement.
03
Do not give PCC without vitamin K for warfarin bleeding, because correction may disappear as the infused factors are cleared.
04
Do not give 10 mg vitamin K for every high INR without bleeding; excessive reversal creates prolonged resistance and avoidable thrombotic-management difficulty.
05
Do not assume a subtherapeutic INR always requires therapeutic LMWH; establish indication, duration below range and actual thrombotic risk first.
06
Do not treat the number while missing a lesion: recurrent iron deficiency, haematuria, postmenopausal bleeding or melaena still requires diagnostic investigation.